The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing

Key Points

• GADEKILL exhibits notable antineuroblastoma activity, especially in relapsed or refractory cases.
• This product targets tumor cells using defined mechanisms involving b7h6 and btn2a1 pathways.
• The analysis highlights low GD2 expression's significance in treatment efficacy against neuroblastoma.
• These findings may enable further development of GADEKILL as an effective immunotherapeutic option.